ARTICLE | Deals
Candid strikes trio of T cell engager partnerships for autoimmunity
BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals
December 17, 2024 12:44 AM UTC
On Monday, Candid entered into partnerships with EpimAb, Ab Studio and Nona, to use the companies’ respective antibody designing platforms to develop T cell engagers (TCE) for autoimmune indications.
Candid Therapeutics Inc. debuted in September with $370 million, and acquisitions of Vignette Bio Inc. and TRC 2004 Inc. under its belt, mobilize bispecific T cell engagers against autoantibody-producing B cells. Via the Vignette Bio deal, it received ex-China rights to BCMA x CD3 bispecific CND106, which originated at EpimAb Biotherapeutics. The TRC2004 acquisition gave it ex-China rights to CND261, a CD20 x CD3 bispecific antibody from Genor that was originally designed by Ab Studio...